| amisulpride / Generic mfg. |
NCT00471588: Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors |
|
|
| Completed | 1 | 52 | Europe | Pramipexole, Amisulpride, Pramipexole, Amisulpride | GlaxoSmithKline | Obsessive-Compulsive Disorder | 12/07 | 12/07 | | |
NCT01972711: Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics |
|
|
| Completed | 1 | 105 | Europe | SEP-363856, Amisulpride, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 07/15 | 07/15 | | |
| Recruiting | 1 | 40 | | ; ; ; | Institute of Clinical Pharmacy, Central South University; Vickmans Laboratories Ltd., Hong Kong, Vickmans Laboratories Ltd.,Hong Kong | Pharmacokinetics | | | | |
| Completed | 1 | 159 | US | amisulpride, Solian, placebo | Mclean Hospital, National Institute of Mental Health (NIMH) | Major Depressive Disorder (MDD) | 05/16 | 05/16 | | |
NCT01701258: An Investigation of Early Life Stress and Depression |
|
|
| Completed | 1 | 153 | US | Amisulpride, Solian, Placebo | Mclean Hospital, National Institute of Mental Health (NIMH), Massachusetts General Hospital | Major Depressive Disorder (MDD), History of Childhood Sexual Abuse (CSA) | 05/17 | 05/17 | | |
CBD-IS, NCT02051387: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study |
|
|
| Completed | 1 | 74 | Europe | Cannabidiol CR, Arvisol, Cannabidiol, Amisulpride, Olanzapine, Quetiapine, Risperidone, Placebo | Central Institute of Mental Health, Mannheim, University of Cologne | Schizophrenia | 08/17 | 08/17 | | |
NCT04849650: PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment |
|
|
| Completed | 1 | 12 | US | Amisulpride IV, Amisulpride Oral Tablet | Acacia Pharma Ltd | Renal Disease, End Stage | 10/21 | 10/21 | | |
NCT04533724: Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia |
|
|
| Not yet recruiting | 1 | 6 | NA | Amisulpride | Shanghai Mental Health Center | Negative Symptom, Schizophrenia, Amisulpride, Gut Microbiomes | 09/22 | 09/22 | | |
NCT04128683: Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa |
|
|
| Active, not recruiting | 1 | 31 | US | amisulpride, Solian, bromocriptine, Parlodel | University of California, San Diego | Anorexia Nervosa | 09/23 | 12/24 | | |
NCT05347199: Effects of a Single Dose of Amisulpride on Functional Brain Changes |
|
|
| Completed | 1 | 127 | Europe | Amisulpride Pill, Placebo | Simone Grimm, Charité Research Organisation GmbH, Boehringer Ingelheim | Major Depressive Disorder | 09/23 | 09/23 | | |
NCT06066112: Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body |
|
|
| Recruiting | 1 | 100 | RoW | Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd., Reference (R) Amisulpride tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd. | The Affiliated Hospital of Qingdao University | Bioequivalence, Schizophrenia | 10/23 | 03/24 | | |
AMEND, NCT04789915: Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis |
|
|
| Recruiting | 1 | 46 | Europe | Memantine, Placebo | Bjorn H. Ebdrup, Lundbeck Foundation, Danish Research Centre for Magnetic Resonance, University of Copenhagen | Psychosis, Negative Symptoms With Primary Psychotic Disorder | 05/25 | 12/26 | | |
